Breast Lesion Localization Methods Market Analysis with Research Report 2020

Global Breast Lesion Localization Methods Market - Growth, Trends, And Forecast (2020 - 2025)

The report presents an in-depth assessment of the Global Breast Lesion Localization Methods including enabling technologies, key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents forecasts for Global Breast Lesion Localization Methods investments from 2020 till 2025.

Click the link to get a Sample Copy of the Report:

https://www.marketinsightsreports.com/reports/04061950941/breast-lesion-localization-methods-market-growth-trends-and-forecast-2020-2025/inquiry?Source=OpenPr&Mode=RJ

The Global Breast Lesion Localization Methods market is highly competitive and consists of a number of major players. Companies, like Becton Dickinson(NYSE: BDX), SOMATEX Medical Technologies, Cook Medical, Cianna Medical, STERYLAB S.r.l, Leica Biosystems, CP Medical, Inc, Elucent Medical, Tsunami S.r.l, M.D.L. srl among others.

Market Overview:

The Breast Lesion Localization Methods Market is expected to register a CAGR of 11.2% during the forecast period. Breast lesion is an abnormal change of the breast tissue which is caused by diseases or injuries. For earlier detection of breast lesions, localization procedures have become necessary in up to 50% of all lumpectomy and surgical biopsy procedures to ensure accurate removal of the target lesion. Breast cancer is the most common type of cancer among women worldwide. According to Breast Cancer Organization, it was estimated that 266,120 new cases of invasive and 63,960 cases of non-invasive breast cancer were diagnosed in the year 2018. According to World Health Organization (WHO), breast cancer is the most frequent type of cancer among women globally, approximately 2.1 million women suffer from breast cancer every year, and with the highest number of cancer-related deaths among women. Increasing prevalence of breast cancer and expanding breast cancer surgeries, technological advancements in breast lesion localization and increasing awareness of early detection of breast cancer are the key driving factors in breast cancer liquid biopsy market.

(Special Offer: Get flat upto 20% discount on this report)

Inquire for Discount:

https://www.marketinsightsreports.com/reports/04061950941/breast-lesion-localization-methods-market-growth-trends-and-forecast-2020-2025/discount?Source=OpenPr&Mode=RJ

Key Market Trends:

Wire Localization Segment is Expected to Hold a Major Market Share in the Breast Lesion Localization Methods Market

- A wire localization biopsy is a procedure used to mark or identify the exact location of a lump or abnormality by using fine wire. Localization biopsy is done before a surgeon does an excisional biopsy to remove the lump.
- According to World Health Organization (WHO), in the year 2018, it was estimated that approximately 627,000 women died from breast cancer that is nearly 15% of all cancer deaths among women globally.
- Wire Localization segment hold a significant market share in the breast cancer liquid biopsy market and is anticipated to show similar trend over the forecast period.
- Increasing prevalence of breast cancer, expanding breast cancer surgeries and technological advancements are the key driving factors in the Wire Localization segment.

Browse the Full report description and TOC at:

https://www.marketinsightsreports.com/reports/04061950941/breast-lesion-localization-methods-market-growth-trends-and-forecast-2020-2025?Source=OpenPr&Mode=RJ

The key insights of the Breast Lesion Localization Methods Market report:

The report provides key statistics on the market status of the Breast Lesion Localization Methods market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.
The report provides a basic overview of the industry including its definition, applications and manufacturing technology.
The Breast Lesion Localization Methods market report presents the company profile, product specifications, capacity, production value, and 2015-2020 market shares for key vendors.
The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.
The report estimates 2020-2025 market development trends of Breast Lesion Localization Methods Market.
Analysis of upstream raw materials, downstream demand and current market dynamics is also carried out
The report makes some important proposals for a new project of Breast Lesion Localization Methods Industry before evaluating its feasibility.

Finally, Breast Lesion Localization Methods Market report is the believable source for gaining the market research that will exponentially accelerate your business. The report gives the principle locale, economic situations with the item value, benefit, limit, generation, supply, request and market development rate and figure and so on. Breast Lesion Localization Methods industry report additionally Present new task SWOT examination, speculation attainability investigation, and venture return investigation.

Latest news and developments:

03 April 2020: BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and BioGX Inc., a molecular diagnostics company, announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for a new diagnostic test that will enable hospitals to screen for COVID-19 (coronavirus) on site and get results in under three hours.

The test helps fill an urgent need across the U.S. for hospitals to access an easy-to-use, rapid diagnostic test to screen patients and health care workers for COVID-19. The test will be run on the BD MAX(TM) System, a molecular diagnostic platform already in use at hundreds of laboratories in nearly every state across the country. Each unit is capable of analyzing hundreds of samples per day.

03 April 2020: Leica Biosystems, the global leader in pathology workflow solutions, announced that it has received notification from the U.S. Food & Drug Administration (FDA) that its Aperio ImageScope DX Viewer with images acquired on the Aperio AT2 DX Scanner can be used for remote diagnosis under emergency use. This application will allow Pathologists to safely view and diagnose Pathology cases from remote locations in response to the COVID-19 pandemic.

Browse Related Reports:

Breast Cancer Therapeutic Market

https://www.marketinsightsreports.com/reports/05241258886/global-breast-cancer-therapeutic-market-size-status-and-forecast-2019-2025?source=OpenPr&Mode=RJ

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format

- Report customization as per the client's requirements

- 3 months of analyst support

How we have factored the effect of Covid-19 in our report:

All the reports that we list have been tracking the impact of COVID-19. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

About Us:
MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Media Contact Us:
Irfan Tamboli (Head of Sales) - Market Insights Reports
Phone: + 1704 266 3234 | +91-750-707-8687
sales@marketinsightsreports.com
irfan@marketinsightsreports.com

This release was published on openPR.